|
|
Vol. 7.22 – 21 June, 2021
|
|
|
|
|
|
|
|
Reserachers explored fibroblast heterogeneity in keloid, a paradigm of fibrotic skin diseases, by using single-cell RNA-seq.
[Nature Communications]
|
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
DERMAL STEM CELLS & TISSUE REGENERATION
|
|
|
|
|
|
Scientists demonstrated that both diabetic foot ulcers and venous leg ulcers exhibited global deregulation of cytoskeletal organization in genomic comparison to normal skin and acute wounds.
[Communications Biology]
|
|
|
|
|
|
Investigators characterized the antimicrobial effects of PLNC8 αβ on cell signaling pathways and inflammatory responses of human keratinocytes infected with S. aureus.
[Scientific Reports]
|
|
|
|
|
|
Topical application of UFP-512 increased the hair length in hair organ cultures and promoted the proliferation and the migration of outer root sheath cells.
[Biomolecules & Therapeutics]
|
|
|
|
|
|
Scientists treated HaCaT cells which resembled human epidermis with IC50 concentration of all-trans-Retinoic Acid-spermine conjugate and analyzed their miRNA expression profile.
[Pharmacogenomics Journal]
|
|
|
|
|
|
|
|
In a BrafV600E PtenF/+ context, researchers showed that BRN2 haplo-insufficiency promoted melanoma initiation and metastasis.
[Nature Communications]
|
|
|
|
|
|
Investigators identified a previously unreported genetic susceptibility to melanoma and melanocytic nevi, familial duplications of gene PPP2R3B.
[Genetics in Medicine]
|
|
|
|
|
|
Identified through screening for cancer-specific endogenous retroviral transcripts, scientists showed that the little-studied E3 ubiquitin ligase HECTD2 exerted dominant control of tumor progression in melanoma.
[Oncogene]
|
|
|
|
|
|
Mechanistically, systemic overexpression of SIRT2 reduced the number of tumor-infiltrating natural killer (NK) cells and suppressed NK cell function and proliferation within the tumor microenvironment.
[Scientific Reports]
|
|
|
|
|
|
|
|
|
Scientists summarize the use of different human cell populations for preclinical and clinical tissue-engineered skin substitutes under research, remarking their strengths and limitations and discuss the future perspectives, which could be useful for wound healing purposes.
[NPJ Regenerative Medicine]
|
|
|
|
|
|
The authors review literature about ongoing and completed clinical trials that applied fibroblasts and bioengineered fibroblasts as therapeutic agents for various skin disorders.
[Dermatologic Therapy]
|
|
|
|
|
|
|
|
Mallinckrodt Pharmaceuticals received FDA approval for its engineered skin product, StrataGraft®, a treatment for serious thermal burns.
[Mallinckrodt Pharmaceuticals, Inc.]
|
|
|
|
|
|
|
|
January 12 – 14, 2022
Shanghai, China
|
|
|
|
|
|
|
|
|
|
|
The University of British Columbia – Vancouver, British Columbia, Canada
|
|
|
|
|
|
|
Brigham and Women’s Hospital – Boston, Massachusetts, United States
|
|
|
|
|
|
|
University of Hawaii Cancer Center – Honolulu, Hawaii, United States
|
|
|
|
|
|
|
Ulsan National Institute of Science and Technology – Ulsan, South Korea
|
|
|
|
|
|
|
University of Michigan – Ann Arbor, Michigan, United States
|
|
|
|
|
|